Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BALANCED SALT vs BREVITAL SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Balanced salt solutions are used for irrigation and replacement of extracellular fluid. They provide essential ions (sodium, potassium, calcium, magnesium, chloride, bicarbonate) to maintain osmotic balance and p H homeostasis. The mechanism involves restoration of electrolyte composition and fluid volume without direct pharmacological activity.
Brevital sodium (methohexital) is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride ion influx and hyperpolarizing neurons, leading to rapid sedation and anesthesia.
Intraocular irrigation during ophthalmic surgery,Irrigation of wounds, body cavities, and tissues during surgical procedures,Replacement of extracellular fluid in hypovolemia (off-label)
Induction and maintenance of general anesthesia,Adjunct to regional anesthesia,Short-duration surgical procedures
Intraocular irrigation during surgery: sufficient volume to maintain anterior chamber depth. Also used as IV fluid: 500-1000 m L bolus, then 50-100 m L/hour continuous infusion for volume replacement.
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15 seconds; maintenance: 0.5-1 mg/kg IV bolus as needed or 50-150 mcg/kg/min IV infusion.
Not applicable; components (sodium, chloride, potassium, calcium, magnesium, acetate, citrate) are endogenous and rapidly equilibrated; clinical context: no terminal elimination half-life as they are physiologic substances
Terminal elimination half-life: 3–6 hours (mean ~4 hours); prolonged in hepatic impairment, obesity, or with repeated dosing due to redistribution.
Not metabolized; components are directly excreted or incorporated into physiological pools. Excess ions are eliminated via renal excretion.
Hepatic metabolism primarily by CYP2C9 and CYP3A4 to inactive metabolites; less than 1% excreted unchanged in urine.
Renal: >95% of electrolytes and water eliminated unchanged via kidneys (glomerular filtration and tubular reabsorption dynamics); biliary/fecal: <5%
Primarily hepatic biotransformation to inactive metabolites (mainly hydroxy-methohexital), with renal excretion of metabolites; less than 1% excreted unchanged in urine. Minor biliary/fecal elimination.
Minimal to none; electrolytes are free in solution; no significant binding to plasma proteins (e.g., albumin, globulins)
Approximately 70–90% bound to albumin.
Approximately 0.2 L/kg (extracellular fluid volume); clinically indicates distribution primarily into interstitial and intravascular spaces
Vd: 1.1–2.5 L/kg (mean ~1.5 L/kg). Larger Vd indicates extensive tissue distribution (highly lipophilic), leading to rapid redistribution and short duration after single bolus.
Intravenous: 100%; ophthalmic: Not applicable (topical administration delivers directly to site, systemic absorption negligible)
IV: 100%. IM: Not well established; likely >90%. Rectal: Variable, ~50–70% due to first-pass metabolism and incomplete absorption.
No dose adjustment required for intraocular use. For IV use, caution in severe renal impairment (e GFR <30 m L/min) with monitoring for electrolyte imbalances; consider reducing infusion rate.
No dosage adjustment required for GFR ≥10 m L/min; for GFR <10 m L/min, reduce dose by 50%.
No adjustment required for either route; balanced salt solution is not hepatically metabolized.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or consider alternative.
Intraocular: as per surgeon's discretion. IV: weight-based, 10-20 m L/kg bolus then 2-5 m L/kg/hour continuous infusion for volume depletion.
Induction: 1-2 mg/kg IV; maintenance: 0.5-1 mg/kg IV bolus or 50-150 mcg/kg/min IV infusion. Contraindicated in infants <2 months with stable BSA.
No specific dose adjustment; monitor for fluid overload and electrolyte disturbances, especially in patients with cardiac or renal compromise.
Reduce induction dose by 50% and administer slowly over 60 seconds; maintenance infusion rates at lower end (50-100 mcg/kg/min).
None.
None.
Hypersensitivity reactions may occur,Use with caution in patients with renal impairment due to risk of electrolyte overload,Monitor serum electrolytes and fluid balance during prolonged use,Do not use if solution is discolored or contains particulate matter
Respiratory depression and apnea may occur; resuscitative equipment must be available,Hypotension and bradycardia possible; use with caution in patients with cardiovascular disease,Extravasation causes tissue necrosis; avoid intra-arterial injection,Seizures may occur in epileptic patients,Rapid injection may cause severe respiratory depression
Hypersensitivity to any component,Severe electrolyte disturbances (e.g., hyperkalemia, hypernatremia),Hepatic failure (relative contraindication due to fluid overload risk)
Known hypersensitivity to barbiturates,Porphyria (may precipitate acute attacks),Severe respiratory insufficiency,Status asthmaticus,Hypovolemic shock or severe hypotension
No known food interactions. Maintain normal hydration unless otherwise instructed.
No specific food interactions are documented for BREVITAL SODIUM. However, patients should avoid heavy meals before anesthesia due to risk of aspiration. Do not consume alcohol or grapefruit juice for 24 hours before and after administration, as they may alter drug metabolism and increase sedation.
No evidence of teratogenic risk; considered safe during all trimesters when used as directed (topical ophthalmic).
Teratogenic potential not fully established in humans. In animal studies, methohexital caused fetal resorptions and malformations at maternally toxic doses. First trimester: Avoid unless essential; risk of neural tube defects cannot be excluded. Second trimester: Limited data, but may cause fetal depression if used near delivery. Third trimester: Crosses placenta; may cause neonatal respiratory depression, hypotonia, and prolonged sedation. Use only if clearly needed with lowest effective dose.
No known risk during breastfeeding; M/P ratio not available, but systemic absorption is minimal.
Excretion into human milk unknown. M/P ratio not determined. Due to short half-life, minimal transfer expected after a single dose. Caution with repeated doses or prolonged infusion. Monitor infant for sedation, feeding difficulties, or respiratory depression.
No dose adjustments required during pregnancy due to negligible systemic absorption.
Pregnancy may increase volume of distribution and clearance, potentially requiring higher initial doses, but the induction dose typically unchanged. Reduced doses may be needed in preeclampsia or cesarean section due to enhanced sensitivity. No specific dose adjustment guidelines; titrate to effect with careful monitoring.
Use a sterile technique for intraocular irrigation. Avoid prolonged corneal exposure. Discard unused solution immediately. Monitor intraocular pressure post-procedure.
BREVITAL SODIUM (methohexital) is an ultrashort-acting barbiturate used for induction of anesthesia and for short procedures. Due to its rapid onset and brief duration, it requires careful titration. It is contraindicated in patients with porphyria. Extravasation causes tissue necrosis; administer only through a secure IV line. It lowers seizure threshold, but can also be used for electroconvulsive therapy (ECT) to induce seizures. Respiratory depression and hypotension are dose-dependent; have resuscitation equipment ready. Avoid in patients with severe hepatic impairment. Coadministration with opioids or benzodiazepines potentiates sedation and respiratory depression.
Report any eye pain, redness, or vision changes immediately.,Do not touch the dropper tip to any surface.,Use as directed by your surgeon.,Discard bottle after single use.
BREVITAL SODIUM is a potent anesthetic that causes rapid loss of consciousness and should only be administered by trained medical professionals.,You may experience temporary pain or burning at the injection site; report any persistent pain or swelling to your healthcare provider.,Drowsiness, dizziness, and confusion may persist for several hours after the procedure; do not drive or operate machinery for at least 24 hours.,Avoid alcohol and other sedatives for 24 hours before and after the procedure as they may increase side effects.,Inform your doctor if you have a history of porphyria, liver disease, or drug allergies.,If you are pregnant or breastfeeding, discuss the risks and benefits with your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BALANCED SALT vs BREVITAL SODIUM, answered by our medical review team.
BALANCED SALT is a Ophthalmic Solution that works by Balanced salt solutions are used for irrigation and replacement of extracellular fluid. They provide essential ions (sodium, potassium, calcium, magnesium, chloride, bicarbonate) to maintain osmotic balance and p H homeostasis. The mechanism involves restoration of electrolyte composition and fluid volume without direct pharmacological activity.. BREVITAL SODIUM is a Barbiturate Anesthetic that works by Brevital sodium (methohexital) is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride ion influx and hyperpolarizing neurons, leading to rapid sedation and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BALANCED SALT and BREVITAL SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BALANCED SALT is: Intraocular irrigation during surgery: sufficient volume to maintain anterior chamber depth. Also used as IV fluid: 500-1000 m L bolus, then 50-100 m L/hour continuous infusion for volume replacement.. The standard adult dose of BREVITAL SODIUM is: Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15 seconds; maintenance: 0.5-1 mg/kg IV bolus as needed or 50-150 mcg/kg/min IV infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BALANCED SALT and BREVITAL SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BALANCED SALT is classified as Category C. No evidence of teratogenic risk; considered safe during all trimesters when used as directed (topical ophthalmic).. BREVITAL SODIUM is classified as Category C. Teratogenic potential not fully established in humans. In animal studies, methohexital caused fetal resorptions and malformations at maternally toxic doses. First trimester: Avoid . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.